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Effect of Percutaneous Coronary Intervention on
Quality of Life: A Consensus Statement from the Society
for Cardiovascular Angiography and Interventions
James C. Blankenship,1* MD, FSCAI, J. Jeffrey Marshall,2 MD, FSCAI,
Duane S. Pinto,3 MD, MPH, FSCAI, Richard A. Lange,4 MD, MBA, FSCAI,
Eric R. Bates,5 MD, FSCAI, Elizabeth M. Holper,6 MD, MPH, FSCAI,
Cindy L. Grines,7 MD, FSCAI, and Charles E. Chambers,8 MD, FSCAI
Percutaneous coronary intervention (PCI) decreases ischemic complications of acute
coronary syndromes. The benefits of PCI in stable ischemic heart disease (SIHD)
depend on its effect on quality of life (QoL), including angina, physical activity, and
emotional well-being. PCI decreases angina and the need for anti-anginal medications,
and increases exercise capacity and QoL, compared with baseline status and com-
pared with medical therapy without PCI. These benefits are greater when QOL is mark-
edly impaired by severe angina before the procedure. When considering treatment
options for symptomatic SIHD, physicians should consider and provide objective data
regarding QoL effects for each treatment strategy. QoL outcomes should be consid-
ered in clinical trials, appropriate use criteria, practice guidelines, and reimbursement
policies for PCI. VC 2012 Wiley Periodicals, Inc.
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INTRODUCTION
Patients have been treated successfully with percuta-
neous coronary intervention (PCI) for over 30 years.
PCI decreases mortality in ST-elevation myocardial
infarction (STEMI) [1–4] and reduces recurrent ische-
mic events (although not mortality) in patients with non-
ST elevation acute coronary syndromes (NSTE-ACS)
[5,6]. The benefit of PCI in STEMI and NSTE-ACS is
accepted and a recent study concluded that 99% of PCI
procedures performed for these clinical situations were
appropriate [7]. However, the value of PCI in patients
with stable ischemic heart disease (SIHD) has recently
been questioned for several reasons. First, studies com-
paring PCI with medical therapy in patients with SIHD
[8–11] demonstrate that PCI is similar but not superior
to optimal medical therapy in preventing death or myo-
cardial infarction (MI). Second, recent studies compar-
ing PCI with medical therapy [8–11] demonstrated
smaller than expected differences in angina relief, espe-
cially over several years of follow-up. Finally, exaggera-
tion or overestimation of the alleged benefits of PCI in
SIHD patients [7,12–17] may contribute to the recently
reported inappropriate use of PCI [7,17].
Since PCI does not decrease the incidence of MI or
death in SIHD patients, its major potential benefit may
be in improving quality of life (QoL), which is worse
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in patients with SIHD compared with those without
SIHD [18]. The benefits of PCI in improving QoL
have been extensively studied and have influenced
guidelines for performance of PCI (Table I), where
QoL is clearly articulated as a primary goal and benefit
of treatment [19,20]. The purpose of this article is to
review the relevant literature describing the effects of
PCI on QoL and recommend how QoL should be used
in guiding therapeutic decisions.
METHODS OF ASSESSING QoL
Outcome metrics such as severity of angina, anti-
anginal medication use, exercise duration, and recur-
rent angina after initial treatment have been used to
assess QoL [21]. However, these outcomes are subject
to confounding factors such as comorbid illnesses, phy-
sician practice patterns, and access to health care. For
example, trials of stents often include angiographic fol-
low-up in which target vessel revascularization may be
performed in the absence of symptoms or QoL impair-
ment. Conventional outcomes such as recurrent MI or
angina relief may not accurately weight or quantify
changes in QoL because they fail to take into account
the patient’s perception of physical, emotional, social,
and psychological well-being. For example, a strategy
based on medical therapy may relieve angina com-
pletely but at the cost of decreased QoL due to drug
side effects or avoidance of valued activities [22]. Con-
sequently, instruments that more comprehensively mea-
sure QoL by assessing the physical, psychological,
social, and functional domains of a patient’s life have
been developed (Table II) [23]. These QoL measures
are essential for the various medical specialties that
focus on improving QoL as part of chronic disease
management. In other medical specialties, studies have
demonstrated that procedures can improve QoL [24–
27]. Post-procedural QoL is influenced by many factors
[28–31] including late procedural complications which
lead to adverse clinical events (e.g., restenosis, recur-
rent angina, and hospitalization) [32,33].
Utilities are an additional method for assessing
patients’ perspectives of their health status. These
scales are determined by a variety of mechanisms (e.g.,
time trade-off, standard gamble or questionnaires
mapped to societal-based utilities). Whereas it is
impractical to measure utilities for every disease state,
when available they can be integrated with survival to
generate quality-adjusted life years (QALYs) that are
important for economic analyses [49–51]. The QALY
TABLE I. Guidelines for PCI for Control of Symptoms
2011 ACC/AHA/SCAI PCI Guidelines to Improve Symptoms [19]
CLASS I
1. PCI to improve symptoms is beneficial in patients with 1 or more significant (70% diameter)
coronary artery stenoses amenable to revascularization and unacceptable angina despite guide-
line-directed medical therapy (GDMT). (Level of Evidence: A)
CLASS IIa
1. PCI to improve symptoms is reasonable in patients with 1 or more significant (70%
diameter) coronary artery stenoses and unacceptable angina for whom GDMT cannot be imple-
mented because of medication contraindications, adverse effects, or patient preferences. (Level of
Evidence: C)
2. PCI to improve symptoms is reasonable in patients with previous CABG, 1 or more significant
(70% diameter) coronary artery stenoses associated with ischemia, and unacceptable angina
despite GDMT. (Level of Evidence: C)
CLASS III: HARM
1. PCI to improve symptoms should not be performed in patients who do not meet anatomic
(50% left main or greater than or equal to 70% non–left main stenosis) or physiological
(e.g., abnormal fractional flow reserve) criteria for revascularization. (Level of Evidence C)
2010 European Society of Cardiology Guidelines on Myocardial Revascularization to Improve
Symptoms [20]
CLASS I
1. Any stenosis >50% with limiting angina or angina equivalent, unresponsive to optimal
medical therapy (OMT). (Level of Evidence: A)
CLASS IIa
1. Dyspnea/CHF and >10% left ventricular ischemia/viability supplied by >50% stenotic
artery. (Level of Evidence: B)
CLASS III
1. No limiting symptoms with OMT. (Level of Evidence C)
‘‘Guideline-directed medical therapy (GDMT) represents optimal medical therapy as defined by
ACCF/AHA guideline recommended therapies (primarily Class I).’’
‘‘Optimal medical therapy (OMT) includes intensive lifestyle and pharmacological management.’’
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is a metric utilized in outcomes research that incorpo-
rates both longevity and QoL and provides a common
scale to compare different therapies. Since many medi-
cal interventions are associated with a variety of clini-
cal outcomes, the QALY is an invaluable common
metric that affords the ability to compare very different
interventions.
Health status measures can be generic, in that they
are applicable to heterogeneous populations with vary-
ing diseases and comorbidities, or disease-specific (i.e.,
explicitly designed to assess the burden of SIHD,
including the symptoms of angina and its associated
limitations) [52–55]. One disease-specific tool for
assessing angina is the Seattle angina questionnaire
(SAQ) which is a 19-item self-administered question-
naire measuring five domains affected by angina: phys-
ical limitation, anginal stability, anginal frequency,
treatment satisfaction, and disease perception. It was
validated against measures such as physician diagno-
ses, nitroglycerin refills, and exercise duration and has
TABLE II. Instruments Commonly Used to Evaluate Health Status and Quality of Life (QoL) in Patients With Stable Ischemic
Heart Disease
Name of instrument Description
Disease-specific quality of life/health status instruments
Ferrans and Powers Quality of Life Index [34] Measures both satisfaction and importance of various aspects of life. Importance
ratings are used to weight the satisfaction response in four dimensions: health and
functioning, socioeconomic, psychological/spiritual, and family
McMaster Health Index Questionnaire [35] QoL measures based on physical, social and emotional functions. Measures are based
on respondent’s feelings and thoughts, but does not relate these to illness.
Medical Outcomes Study Short-Form 36
(SF-36) [36]
Consists of eight scaled scores, which are the weighted sums of the questions in their
section measuring vitality, physical functioning, bodily pain, general health perceptions,
physical role functioning, emotional role functioning, social role functioning and mental
health. RAND-36 includes same items but is scored differently.
Short-Form 12 [37,38] Shortened version of SF-36 and has been found to correlate well with the SF-36
summary scores in various disease states including angina
Nottingham Health Profile [39] Evaluates six dimensions of health subjectively including: physical mobility, pain,
social isolation, emotional reactions, energy, and sleep as well as statements about
seven areas of life that are most affected by health status. Most useful for chronic
and pronounced symptoms and for detecting treatment effects.
Psychological Well-Being Index [39,40] Composed of six dimensions divided into 22 items: anxiety, depression, positive mood,
vitality or energy, self-control repertories, overall health-related perceptions of
illness. Suitable for evaluating the impact of symptoms on well-being and applicable
for both healthy and patient populations.
Quality of Well-Being Scale [41] Based on the societal preferences associated with a person’s level of functioning at
specific point in time. Averages values across three ratings of functioning: mobility,
physical activity, social activity, and across one rating of symptomatic complaints
that might inhibit function.
Sickness Impact Profile (SIP) [42] Everyday activities in 12 categories (sleep and rest, emotional behavior, body care and
movement, home management, mobility, social interaction, ambulation, alertness
behavior, communication, work, recreation and pastimes, and eating) are measured.
Scoring can be done at the level of categories and dimensions as well as at the total
SIP level.
Swedish Health-Related Quality of Life Survey [43] Consists of 61 items that form 11 multi-item scales assessing aspects of physical,
mental, social and general health
Duke Activity Status Index (DASI) [44] A 12-item scale measuring functional status. Asks questions about common activities
and correlates with peak oxygen consumption.
Disease-specific quality of life/health status instruments
MacNew Instrument (QoL after Myocardial
Infarction Instrument (QLMI) or QLMI-2) [45]
27 items assessing three factors: social functioning, physical functioning and emotional
functioning.
Seattle Angina Questionnaire (SAQ) [46] Five scales to assess dimensions of coronary artery disease: physical limitation, angina
stability, angina frequency, treatment satisfaction, and disease perception.
Demonstrated to be responsive to both major changes in clinical status (i.e.,
improvement in angina-related problems as a result of angioplasty) and smaller
changes in angina-related functional status.
Myocardial Infarction Dimensional Assessment
Scale [47]
Covers seven areas of health status (physical activity, insecurity, emotional reaction,
dependency, diet, concerns over medications and side effects).
Physical Activity Score [48] Evaluates one dimension in estimating physical capacity for patients with angina
pectoris
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subsequently been shown to be prognostic of outcome
[56]. The SAQ can distinguish treatment effect from
the influences of comorbid illness and is more sensitive
to subtle changes in clinical condition than are generic
measurement tools [46,57].
Some symptoms of active ischemic heart disease
(e.g., dyspnea/breathlessness, energy/fatigue) are not
well captured in the current disease-specific scales but
may be important to patients [58]. The absence of
these dimensions from QoL measures may lead to
underestimation of the benefits of therapies for SIHD.
Outcomes After PCI in Patients Presenting
With STEMI/NSTE-ACS
Studies of outcomes after STEMI/NSTE-ACS have
generally focused on adverse events such as recurrent
MI, recurrent ischemia, and late revascularization
rather than QoL. Since these outcomes are known to
affect QoL, they are briefly summarized here.
Primary PCI for STEMI has several advantages
compared with fibrinolytic therapy. In pooled analyses,
primary PCI is associated with reduced mortality,
stroke, intracranial hemorrhage, reinfarction, and recur-
rent ischemia compared with fibrinolysis [2,59–62].
Analyses examining 12 month costs in terms of cost
per event-free survivor found that expenditures were
lower in the PCI cohorts than in the fibrinolytic-treated
patients [63–66]. For STEMI, use of stents compared
with balloon angioplasty is associated with early (i.e.,
6 months) improvement in QoL as manifested as
reduced angina frequency, less bodily pain, and
improved disease perception [67].
A routine invasive strategy in patients with NSTE-
ACS reduces (a) the composite risk of death or non-
fatal MI [6,68] (particularly in patients with ischemic
ECG changes, positive biomarkers, or advanced age),
(b) severe angina [6,69], and (c) rehospitalization over
the ensuing 1–2 years [6], as compared with an ische-
mia-guided approach. Compared with a non-invasive
strategy, an invasive strategy reduces (a) duration of
initial hospital stay [70,71], (b) readmission rate [71–
73], (c) anginal symptoms [69,71,74], and (d) the num-
ber of required anti-anginal medications [71,74]. Stud-
ies have also demonstrated greater gains in QoL with
an invasive strategy leading to PCI when appropriate
compared with a strategy of medical therapy in ACS
patients [74–77].
QoL After PCI in Patients With SIHD
Several types of studies have been used to evaluate
the effect of PCI on QoL in SIHD patients. Observatio-
nal cohort studies that compare baseline to post-PCI
QoL provide the lowest quality of evidence, as they are
subject to bias and placebo effect and likely exaggerate
the true benefits of PCI (Table III). Observational studies
that compare patients undergoing PCI to a cohort receiv-
ing medical therapy alone or coronary artery bypass
graft (CABG) surgery (Table IV) provide higher quality
evidence, but are still subject to bias. The highest quality
evidence comes from randomized controlled studies
comparing PCI to alternative treatments (Tables V and
VI), although these are also subject to enrollment biases
that may prevent conscription of the very patients who
might benefit most, and to crossover that obscures the
effects of the original treatment assignment.
Multiple studies have demonstrated that PCI
improves QoL [9,10,52,54,55,58,78–86,89,93,103–110]
and exercise capacity [78,79,85,86,111] compared with
pre-PCI status. The magnitude of improvements in
QoL correlated with improvements in outcomes follow-
ing PCI [112].
Effect of PCI on QoL Compared With
Medical Therapy
In studies of patients with SIHD, PCI has been more
effective than medical therapy in relieving angina
[8,11,87,94,97,106,113–119], reducing the use of anti-
anginal drugs [117], and improving exercise capacity
[8] and QoL [9,58,82,94,114] (Tables III and IV).
Improved QoL with PCI compared with medical ther-
apy (Table V) has been reported at late follow-up 5–8
years post procedure [114,118] but not at 3 years post
procedure [113].
A meta-analysis of 14 randomized, controlled trials
of PCI versus medical therapy in 7,818 patients en-
rolled from 1987–2005 showed that complete angina
relief was superior with PCI (odds ratio: 1.69, 95%
confidence interval: 1.24–2.30) [120] with the benefit
limited to trials that enrolled patients before the year
2000. In pooled analysis of studies that enrolled
patients after 2000, angina relief was similar for both
therapies, which may be attributable to improved medi-
cal therapy. An alternative explanation is that the
recent studies in this analysis enrolled patients with a
low prevalence of significant angina at baseline. Spe-
cifically, two-thirds of patients in the Clinical Out-
comes Utilizing Revascularization and Aggressive drug
Evaluation trial [COURAGE] [113] had angina weekly
or less frequently and 77% in the Open Artery Trial
(OAT) [100] had no angina, perhaps rendering PCI—
or any intervention—unlikely to improve angina symp-
tom control. Non-randomized studies enrolling patients
after 2000 with a higher prevalence of angina than
COURAGE or OAT have demonstrated significantly
better QoL with PCI compared with medical therapy
[9,82,87,94,97,116–119].
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TABLE III. Studies of Quality of Life (QoL) Post-Percutaneous Coronary Intervention (PCI) versus Pre-PCI in PCI Cohort Studies
Author date Study design
N






PCI Cohort in Single Cohort Studies (PCI only)










all domains of QoL at
6 weeks





in 72% of patients
at 1 month











NHP and DASI both
statistically significantly
improved at 1 month
and 3 years (P < 0.01)
Seto, 2000 [81,82] Prospective cohort
of PCI patients
1445 SF-36, SAQ nr QoL improved in 58–75%
of patients for different
domains at 6 months
Spertus, 2004 [82] Prospective cohort
of PCI patients
1020 SAQ nr 85% had ‘‘clinically
significant improvement’’
at 1 year
Lowe, 2004 [83] Prospective cohort
of PCI patients ‘‘ not
appropriate for PCI’’
21 SAQ nr No significant improvement
in any domain at 1 year
Wong, 2007 [84] Prospective cohort of
Chinese PCI patients
78 SF-36, SAQ nr Statistically significant
improvements in 6 of
8 SF36 and 5 of 5 SAQ
domains at 1 and
3 months
Grantham, 2010 [85] Prospective cohort
of PCI patients with
chronic total occlusion
125 SAQ nr ‘‘significant improvement’’
in QoL at 1 month
Melberg, 2010 [86] Prospective cohort
of PCI patients
609 SF-36 nr ‘‘Significant improvement’’
in nearly all domains
at 6 months
De Quadros, 2011 [87] Prospective cohort
of PCI patients
110 SAQ 5% pre/68% post




of patients in 4 out of
5 SAQ domains at 6
and 12 months
PCI Cohort in Multi-Cohort Studies
Brorsson, 2001 [43] Prospective cohorts of
PCI and CABG patients
349 SWED-QUAL 3% pre/51% post
(P < 0.05) at
4 years
Statistically significant
improvements in all 5
domains of SWED-QUAL
at 6, 21, and 48 months
Borkon, 2002 [88] Prospective cohorts of
PCI and CABG patients
252 SAQ nr All domains of SAQ improved
at 6 and 12 months
Kattainen, 2005 [89] Prospective cohorts of PCI
and CABG patients
183 15D nr QoL significantly improved
versus baseline at 6
and 12 months.
Loponen, 2009 [90] Prospective cohorts of PCI
and CABG patients
229 15D 2% pre/58% post
at 3 years
QoL better at 6 months but
not at 3 years; angina




Prospective cohorts of PCI
and CABG patients
585 SF-36 7% pre/90% post
at 3 years
Significant improvement in
all 8 domains of SF-36 at
6 months and 3 years
Brooks, 2010
BARI-2D [92]
Prospective cohort of PCI
patients and CABG patients
796 DASI,
Rand scales
17% pre/60% post Data not available for
PCI group alone
ARTS, Arterial Revascularization Therapies Study; BARI-2D, Bypass Angioplasty Revascularization Investigation—2 Diabetes; CABG, coronary
artery bypass graft surgery; DASI, Duke Activity Status Index; Nr, Not reported; PCI, Percutaneous coronary intervention; SAQ, Seattle Angina
Questionnaire; SF-36, Short Form 36; SWED-QUAL, Swedish Quality of Life Survey.
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The misperception that PCI improves QoL only min-
imally may be fueled by a misunderstanding of the
COURAGE [113] and Bypass Angioplasty Revascular-
ization Investigation 2 Diabetes (BARI-2D) [92] treat-
ment strategies. Since these studies compared medical
therapy with revascularization as initial treatment strat-
egies, crossover from medical therapy to revasculariza-
tion therapy for relief of unacceptable symptoms was
frequent (33% of patients in COURAGE and 42% of
patients in BARI-2D). Because higher than anticipated
crossover rates in clinical trials reduces the ability to
detect differences in the treatment groups this may
have obscured long-term differences in symptoms
between the initial treatment assignment to PCI or
medical therapy [92,113].
The writing group could find only two studies failing
to show a benefit of PCI on QoL. Patients randomized
to PCI versus exercise training reported similar
improvements in angina [105]. In patients deemed
unsuitable for any revascularization, salvage PCI did
not improve QoL but slightly improved angina status
compared with baseline [83].
Effect of PCI on QoL Compared With CABG
Many studies have compared PCI with CABG for
angina control and QoL improvement (Table VI). Both
procedures improve angina and QoL compared with
baseline [88,91,94,96,97,99,121,122]. QoL is better af-
ter PCI than after CABG in the first months after the
TABLE IV. Studies of Quality of Life (QoL) Post-Percutaneous Coronary Intervention (PCI) versus Pre-PCI in PCI Arm of
Randomized Studies
Author, date,








Randomized to PCI versus
medical therapy
504 SF-36 nr 33% rated health at
1 year as ‘‘much better’’;




Single vessel coronary dis-
ease randomized to PCI
versus medical therapy









Two vessel coronary dis-
ease randomized to PCI
versus medical therapy









Randomized to PCI versus
atorvastatin
177 SF-36 Angina improved
in 54% at 18
months




Randomized to PCI versus
medical therapy





Randomized to PCI versus
medical therapy
1149 RAND-36 SAQ 21% pre/59%
post at 3 years
QoL score
improved approx










nr All 8 NHP domains





ease randomized to PCI
or CABG
488 SAQ nr QoL improved at 6 months
and 1 year (P < 0.01)
Thiele, 2009 [98] Isolated proximal left ante-
rior descending disease
randomized to PCI or
CABG
65 SF 36, McNew nr All 8 SF-36 and all 4
McNew domains




Multi-vessel or left main
coronary disease
randomized to PCI or
CABG
903 SF-36, SAQ 22% pre/72%
post at 12
months
QoL score improved signifi-
cantly from approx 45 at
baseline to approx 75 at
6 and 12 months
ACME, angioplasty compared with medical therapy; AVERT, atorvastatin versus revascularization treatment; CABG, coronary artery bypass graft
surgery; COURAGE, clinical outcomes utilizing revascularization and aggressive drug evaluation; CABRI, coronary angioplasty versus bypass revas-
cularization investigation; MASS II, medicine, angioplasty, or surgery study; NHP, Nottingham health profile; NR, not reported; PCI, percutaneous
coronary intervention.
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procedure [88,90,99,109,123–126]. Return to work
occurs earlier with PCI-treated patients compared with
CABG, but at 3–5 months the rate is similar
[40,124,127].
Fewer patients reported angina at 1 year follow-up
with CABG compared with PCI in a collaborative
analysis of data from 6,528 patients enrolled in 10
randomized trials of CABG versus PCI (14% versus
26%, P < 0.001) [128]. A systematic review of 23
randomized studies of CABG versus PCI reported that
angina relief at 1, 3, and 5 years was better for CABG
than PCI [129]; at 5 years the incidence of freedom
from angina was 84% for CABG and 79% for PCI (P
< 0.001). Most but not all observational studies docu-
ment better angina relief and QoL with CABG at 6
months to 4 years of follow-up when compared with
PCI [52,90,117,126,130].
Drug eluting stents (DES) compared with historic
CABG controls were associated with better QoL at 1
year and similar QoL at 3 year follow-up [91]. The
SYNergy Between PCI with TAXus and Cardiac Sur-
gery (SYNTAX) trial demonstrated a small but signifi-
cant reduction in angina frequency with CABG com-
pared with DES at 6 and 12 months in patients who
had frequent (i.e., daily or weekly) angina at baseline,
but not in those with less frequent symptoms [99].
With long-term follow-up (e.g., >5 years), differen-
ces in angina-free status between PCI and CABG tend
to decrease due to return of angina in CABG patients
and cross-over to CABG in patients initially treated
with PCI [102,131]. Findings during long-term follow-
up stem, in part, from the fact that stent failure tends
to occur over months, while vein graft attrition and
related symptoms onset over years.
In patients with left main or single vessel proximal
left anterior descending artery disease, PCI (compared
with CABG) produced similar QoL at 6–12 months
[98,132–134] but more frequent angina at 5 years [11].
TABLE V. Studies of Quality of Life (QoL) After Percutaneous Coronary Intervention (PCI) Compared With Medical Therapy
Author, date,














177/164 SF36 nr QoL similar at 6 and 18







504 /514 SF-36 65% PCI/ 47% MT
(P < 0.05) at
1 year
QoL better than MT for PCI
at 3 months and 1 year







105 /107 McMaster Health
Index Ques-
tionnaire
nr QoL scores better in PCI











(P ¼ 0.09) at
6 months














1149 /1138 RAND-36 SAQ 53% PCI versus 42%
MT (P <0.001) at
3 months
Both groups improved from
baseline. QoL better for
PCI than MT at 3 and








1082 /1084 DASI SF-36 93% PCI / 88% MT
(P ¼ 0.03) at
24 months
QoL better with PCI at
6 months but not at 12
or 24 months by DASI;
no difference by SF-36
at 6, 12, or 24 months
ACME, angioplasty compared with medical therapy; AVERT, atorvastatin versus revascularization treatment; BMS, bare metal stents; CABG, coro-
nary artery bypass graft surgery; COURAGE, clinical outcomes utilizing revascularization and aggressive drug evaluation; DASI, duke activity status
Index; DES, drug eluting stents; MASS, medicine, angioplasty, or surgery study; MI, myocardial infarction; nr, not reported; NHP, Nottingham
health profile; PCI, percutaneous coronary intervention; OAT, occluded artery trial; PTCA, percutaneous transluminal coronary angioplasty; QoL,
quality of life; RITA, randomized intervention treatment of Angina; SAQ, Seattle angina questionnaire; SF, short form. TIME, trial of invasive ver-
sus medical therapy in elderly patients with chronic symptomatic coronary artery disease.
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QoL After PCI in Specific Patient Subsets
Gender. QoL is better in men who undergo revascu-
larization for CAD as compared with similarly treated
women [87,92,94,117,135,136]. This finding is due in
part to the facts that men report better QoL at baseline
compared with women, and baseline QoL is a strong
predictor of post-revascularization QoL. Another con-
tributing factor is that women have more recurrent an-
gina after PCI than men [137,138].
Elderly. Elderly patients with symptomatic CAD
have improved QoL with PCI and derive a similar or
greater improvement than younger patients, despite
having a higher risk profile at presentation
[81,82,85,104,108 139–141]. Neither of the age-specific
TABLE VI. Selected Studies of Quality of Life (QoL) After Percutaneous Coronary Intervention (PCI) Compared With Coronary
Artery Bypass Surgery (CABG)
Author, date, trial










1- or 2-vessel disease
252/349 SWED-QUAL 57% CABG/51%
post PCI at 4 years
QoL better with CABG at
6 months but similar at





256/757 SWED-QUAL QoL better with CABG at 6
and 21 months (P < 0.05)





510/501 NHP 78% CABG/ 69%
PCI ((P ¼ 0.007)
at 2 years
QoL borderline significantly
better for CABG than PCI







74/80 NHP nr QoL similar for PCI and





252 /223 SAQ nr Angina frequency and QoL
better for CABG than PCI






488 /500 SAQ nr Angina frequency and QoL






to PCI or CABG or
medical therapy
180/175 SF-36 nr QoL for CABG better than
PCI at 1 year. QOL for
CABG and PCI better












nr QoL better for CABG than
PCI through 3 years but
similar from 3–10 years
Thiele, 2009 [98] Isolated proximal left
anterior descending
disease randomized
to PCI versus CABG
65/65 SF 36, McNew CABG 74% /PCI
81% (P ¼ 0.05)
at 12 months









583 ¼ (DES) 483
¼ (BMS) 492
¼ (CABG)
SF-36 CABG 87.0%/ PCI
with DES 90.0% /
80% PCI with
BMS at 12 months
QoL better after DES than
CABG up to 1 year and
similar at 3 years
Cohen, 2011,
SYNTAX [99]




903 /897 SF-36 SAQ Similar at 1 and 6
months; CABG
76% versus PCI
72%, P ¼ 0.05
at 1 year
QoL better for PCI at
1 month and worse
for PCI at 12 months
compared with CABG
ACME, angioplasty compared with medical therapy; ARTS, arterial revascularization therapies study; BARI, bypass angioplasty revascularization
investigation; BMS, bare metal stents; CABG, coronary artery bypass graft surgery; CABRI, Coronary Angioplasty versus Bypass Revascularization
Investigation; CAD, coronary artery disease; COURAGE, clinical outcomes utilizing revascularization and aggressive drug evaluation; DASI, duke
activity status index; DES, drug eluting stents; NHP, Nottingham health profile; NS, not significant; OAT, occluded artery trial; PCI, percutaneous
coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; QoL, quality of life; RITA, randomized interventions treatment of
angina; SAQ, Seattle angina questionnaire; SF, short form, SoS, stent or surgery; SYNTAX, SYnergy between PCI with TAXUS and CABG.
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subgroups in the SYNTAX trial (<75-year old versus
>75-year old) had differences between PCI and CABG
in the SAQ angina frequency subscale at 6 or 12
months; there was no interaction between age and an-
gina status. [99].
Diabetes. The BARI 2D trial showed improvement
in angina with PCI compared with medical therapy,
but otherwise similar QoL measurements [92,115]. The
SYNTAX trial did not demonstrate significant differen-
ces in QoL scores for CABG versus PCI-treated dia-
betic patients [99].
Prior CABG. In a retrospective study of patients
with recurrent ischemia following CABG, PCI of the
native vessel or bypass graft significantly improved an-
gina compared with baseline [142].
Other Subgroups. Data regarding QoL after PCI in
patients with chronic kidney disease or congestive
heart failure is lacking.
Factors Affecting QoL After PCI
Not all patients who undergo PCI experience
improved QoL [8,55,107,143]. Post-PCI QoL is
affected by several factors (Table VII).
Increased frequency of angina and greater extent of
myocardial ischemia at baseline correlate with greater
improvements in QoL after PCI [9,82,85,96,99,145,15],
as do post-PCI freedom from angina [55,80,89,152
158,159] and freedom from repeat revascularization
post-PCI [153]. However, patients attach limited im-
portance to repeat PCI for restenosis [160]. A time
trade-off study demonstrated that patients would be
willing to sacrifice less than a week of life out of an
expected 10-year life span to avoid an episode of reste-
nosis [161].
In randomized trials, cardiac rehabilitation reduces
hospital readmission and clinical event rates and
improves QoL after PCI [146,147]. Non-smoking status
after PCI correlated with better QoL compared with
smoking [92,144,146] and patients that quit have better
health status outcomes than those that continue smok-
ing [144,150]. Co-morbidities (e.g., depression, conges-
tive heart failure, increasing body mass index and neu-
ropathy) [54,80,92,162], lower socioeconomic status
[153], and unemployed status [55,154] after PCI corre-
late with lower QoL.
Sexual activity is a component of QoL [155]. Sexual
dysfunction is more prevalent in patients with SIHD
[163], but it is unclear whether it is improved by PCI
[164]. Patients with erectile dysfunction may be unable
to take phosphodiesterase inhibitors (e.g., sildenafil)
because they have angina treated with long-acting
nitrates or sub-lingual nitroglycerine. PCI that removes
the need for nitrates and allows use of phosphodiester-
ase inhibitors to treat erectile dysfunction might
improve sexual functioning and QoL in selected
patients [165].
Ethical Principles in Decisions Regarding
Therapy and QoL
The fundamental principles of medical ethics are
beneficence (‘‘do good, avoid harm’’), autonomy, and
distributive justice [166]. The first two are most rele-
vant to PCI and QoL. Beneficence represents the duty
of the physician to provide care that produces the
greatest benefit to the patient. Autonomy describes the
physician’s responsibility to help the patient make
informed decisions. These principles should influence
how physicians conduct informed consent discussions
and advise patients about preferred therapies [167].
Informed Consent. The physician has the responsi-
bility for presenting treatment options and the pros and
cons of each alternative [167]. This may require in-
quiry into the patient’s values to identify important
preferences. The physician should discuss the likeli-
hood of survival, MI, stroke, repeat revascularization
procedures, and QoL associated with the treatment
options. This discussion should be personalized for
each patient to include anticipated risks and benefits.
For many patients, the treatment options carry similar
risks of death and MI and therefore QoL assumes rela-
tively greater importance. In these cases, physicians
should explain that for some but not all patients QoL
is most improved by PCI or CABG in the most symp-
tomatic patients, and least improved with revasculariza-
tion in patients who are asymptomatic or only mildly
symptomatic.
Advising Patients on Choice of Strategy. For most
patients, survival dictates the choice of treatment strat-
egy. When survival is similar among various strategies,
patients usually base decisions on their perceptions of
how each strategy affects QoL.
Given a choice, most patients prefer a strategy that
is easier in the short-term (e.g., PCI) over a strategy
that is more complicated in the short-term (e.g.,
CABG), even when the more complicated strategy pro-
duces better long-term results (e.g., less angina or bet-
ter QoL). Since most patients make these value judg-
ments—so called temporal discounting—without this
understanding [168], the physician should make
patients aware of the trade-offs they are considering.
Cardiologists face several challenges to their objec-
tivity when making treatment recommendations. First,
patients and physicians frequently over-estimate the
benefit of revascularization procedures compared with
noninvasive medical therapies [12,13–15,169]. Sec-
ond, physicians express more regret about adverse
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outcomes associated with inaction (not performing
PCI) than complications associated with performing
PCI (the ‘‘chagrin factor’’) [170] even though the out-
come may be the same (i.e., death of the patient).
Third, the reimbursement model for United States
health care incentivizes performance of procedures.
Therefore, the physician must accurately advise the
patient about the pros and cons of each treatment al-
ternative and help the patient arrive at the treatment
decision most consistent with the patient’s values and
preferences [128].
CONCLUSIONS AND RECOMMENDATIONS
1. While the overiding goal in performing PCI in
patients with STEMI and NSTE-ACS is to reduce
morbidity and mortality, appropriate early cardiac
catheterization and PCI is associated with
improved QoL in patients without serious comor-
bidities.
2. PCI for treatment of SIHD improves QoL and an-
gina, compared with baseline, and compared with
medical therapy, with the following limitations:
TABLE VII. Studies Identifying Predictors of Post-Percutaneous Coronary Intervention (PCI) Quality of Life (QoL)





health status Other factors
Improvement in QoL
correlates with sever-
ity of baseline angina
McKenna, 1994 [79] Post-PCI 209 nr Restenosis/ revascularization nr
Nash, 1999 [54] Post-PCI 1182 þ Prior CABG, elderly nr
Permanyer-Miralda,
1999 [80]
Post-PCI 106 þ Post-PCI angina, dyspnea,
restenosis/ revascularization
nr
Taira, 2000 [145] Post-PCI 1432 nr Continued smoking post-PCI nr
Bourassa, 2000 [146] Post PCI or CABG
in BARI Trial
1095 nr nr þ
Belardinelli, 2001 [147] Post-PCI 118 nr Randomization to no exercise
training
nr
Rumsfeld, 2001 [127] Post-PCI or CABG 389 þ COPD, CKD, diabetes, current
smoker
nr
Higgins, 2001 [148] Post-PCI 99 nr Randomization to no cardiac
rehab
nr
Brorsson, 2001 [149] Post-PCI or CABG 601 nr Female, heart failure nr
Jamieson, 2002 [150] Post-PCI or CABG 301 þ Female elderly nr
Borkon, 2002 [88] Post-PCI 252 nr Restenosis/ revascularization nr
Haddock, 2003 [151] Post-PCI 271 nr Current smoker nr
Zhang, 2003 [97] Post-PCI 488 nr Restenosis/ revascularization nr
Zhang, 2004 [136] Post-PCI in SOS
Trial
388 nr Female nr
Hlatky, 2004 [152] Post-PCI or CABG
in BARI Trial
934 nr nr þ
Spertus, 2004 [82] Post-PCI 1518 þ Age þ
Spertus, 2005 [153] Post-PCI 1027 nr High risk for restenosis nr
Denvir, 2006; Leslie,
2007 [154,155]
Post-PCI 1346 nr Low socioeconomic status,
unemployment
nr
Hofer, 2006 [124] Post-PCI 432 nr Depression, anxiety nr
Favarato, 2007 [94] Post-PCI 180 nr Female nr
Weintraub, 2008 [9] Post-PCI in
COURAGE
1149 nr nr þ
Kriston, 2010 [156] Post-PCI or
CABG
493 nr Sexual dysfunction, depression nr
Grantham, 2010 [85] Post-PCI 125 nr nr þ
Brooks, 2010 [92] Post-PCI or CABG
in BARI-2D Trial
2368 nr Female, elderly, angina,
smoking, heart failure
nr
Rittger, 2011 [157] Post-PCI 95 nr Elderly nr
De Quadros, 2011 [87] Post-PCI 110 þ nr þ
BARI, bypass angioplasty revascularization investigation; BARI-2D, bypass angioplasty revascularization investigation—2 diabetes Trial; CKD,
chronic kidney disease; COPD, chronic obstructive pulmonary disease; COURAGE, Clinical outcomes utilizing revascularization and aggressive drug
evaluation trial; nr, not reported; PCI, percutaneous coronary intervention; QoL, quality of life; SoS, stent or surgery trial.
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a. QoL improvement after PCI is proportional to the
severity of angina before PCI and adequacy of
revascularization.
b. Some co-morbidities limit QoL before and after
PCI and may minimize any improvement in QoL
resulting from PCI.
c. QoL benefits of PCI over medical therapy decrease
over time due to cross-over from medical therapy
to PCI, the efficacy of optimal medical therapy,
and restenosis or progression of atherosclerosis.
3. QoL after PCI compared with CABG is better in the
short-term (months), worse in the intermediate term
(1–5 years), and probably similar in the long-term
(>5 years) due to bypass graft failure, progression
of atherosclerosis in native vessels, and cross-over
from PCI to CABG.
4. Many SIHD patients and physicians tend to over-
estimate the benefits of revascularization procedures
and underestimate the safety and effectiveness of
medical therapy.
5. When there is equipoise in the risks/benefits of med-
ical therapy compared with PCI, the preferences of
the fully informed patient should play a major role
in treatment decisions.
6. Policymakers should consider QoL issues and allow
for patient preferences when developing clinical tri-
als, appropriate use criteria, practice guidelines, and
reimbursement policies for PCI.
7. The importance of QoL issues should be considered
in all aspects of PCI care from the physician’s ini-
tial assessment of potential benefit through the pub-
lic reporting of results.
8. Additional research is needed to accomplish the fol-
lowing:
a. Prospectively document the baseline and follow-
up QoL in SIHD patients treated with medical
therapy alone versus medical therapy with PCI
versus medical therapy with CABG, including
specific subgroups such as women, diabetics, the
elderly, and those with chronic kidney disease,
heart failure, or prior CABG.
b. Identify subgroups of SIHD patients for whom
PCI is particularly effective in improving QoL
(e.g., patients with QoL limited only by severe
angina) and for whom PCI is relatively ineffective
in improving QoL (e.g., patients with minimal
angina or with baseline poor QoL due to multiple
intractable co-morbidities). Build prediction mod-
els of health status outcomes that could better
inform patients and physicians of likely outcomes
of medical therapy, PCI, and CABG.
c. Identify optimal methods of educating patients
and physicians about expected outcomes of dif-
ferent treatment options and integrate optimal
education methods into routine informed consent
processes.
New innovations in revascularization and medical
therapy will require ongoing reassessment of QoL after
PCI. For example, most of the studies cited here did
not use DES; reductions in restenosis due to DES may
further improve QoL post-PCI. Additional insights into
post-PCI QoL are expected from the proposed Interna-
tional Study of Comparative Health Effectiveness with
Medical and Invasive Approaches (ISCHEMIA) Trial
randomizing 8,000 patients with moderate ischemia on
stress testing to catheterization and revascularization
versus optimal medical therapy.
In summary, PCI decreases mortality and ischemic
events and improves QoL in patients with STEMI and
NSTE-ACS. In SIHD patients, PCI may improve
symptoms and QoL, with the greatest benefits in
patients with few co-morbidities, severe angina, and
potential for complete revascularization. SIHD patients
with severe co-morbidities or minimal ischemic symp-
toms benefit minimally from PCI. For many SIHD
patients, an initial treatment strategy of PCI is superior
to medical therapy in improving QoL in the short-term.
QoL differences between PCI versus CABG vary as
time elapses after the procedure. QoL differences
among these treatment strategies are small enough and
individual patients’ responses to treatment are variable
enough that patient preferences must be considered in
choosing treatment strategies for SIHD.
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